Details for Patent: 12,178,815
Which drugs does patent 12,178,815 protect, and when does it expire?
Patent 12,178,815 protects CABENUVA KIT and is included in one NDA.
This patent has twenty patent family members in thirteen countries.
Summary for Patent: 12,178,815
| Title: | Regimens for treating HIV infections and aids |
| Abstract: | A method of treating HIV comprising intramuscular administration once every 4 weeks or less frequently of a combination of cabotegravir or a pharmaceutically acceptable salt thereof and rilpivirine or a pharmaceutically acceptable salt thereof, including the option of discontinuing administration of a first oral anti-retroviral regimen and intramuscularly administering, once four weeks or less often said combination of cabotegravir and rilpivirine. |
| Inventor(s): | Herta CRAUWELS, David Margolis, William R. SPREEN, Andrew Spaltenstein, Peter Williams |
| Assignee: | Janssen Pharmaceutica NV , Janssen Cilag Ltd , Janssen Sciences Ireland ULC , ViiV Healthcare Co |
| Application Number: | US18/762,939 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; |
Drugs Protected by US Patent 12,178,815
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | CABENUVA KIT | cabotegravir; rilpivirine | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212888-001 | Jan 21, 2021 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG | ⤷ Start Trial | ||||
| Viiv Hlthcare | CABENUVA KIT | cabotegravir; rilpivirine | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 212888-002 | Jan 21, 2021 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,178,815
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 112282 | ⤷ Start Trial | |||
| Australia | 2018304591 | ⤷ Start Trial | |||
| Australia | 2021261965 | ⤷ Start Trial | |||
| Canada | 3070319 | ⤷ Start Trial | |||
| Chile | 2020000176 | ⤷ Start Trial | |||
| China | 111107850 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
